Harbin Pharmaceutical Group's (SHA:600664) unit, Harbin Pharmaceutical Group Sanjing Mingshui Pharmaceutical, received approval from China's National Medical Products Administration for the marketing of its active pharmaceutical ingredient, ferric protein succinate, according to a Shanghai bourse filing on Friday.
The pharmaceutical company invested 8.3 million yuan into the research and development of the product, which is an organic iron compound.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.